Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, 24-Week Study to Evaluate the Efficacy and Safety of INT131 Besylate Compared to Pioglitazone in Subjects With Type 2 Diabetes

NCT00631007 is registered in ClinicalTrials.gov with InteKrin Therapeutics, Inc. as lead sponsor.

NCT NCT00631007
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00631007 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, 24-Week Study to Evaluate the Efficacy and Safety of INT131 Besylate Compared to Pioglitazone in Subjects With Type 2 Diabetes
Lead sponsor
InteKrin Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
February 29, 2008
Completion date
September 30, 2009
Enrollment
367 (actual)
Sites
66

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes mellitus